Acadia Q1 revenue rises 10% to $268 million, but net income falls to $4 million
Acadia Pharmaceuticals reported first quarter 2026 total revenues of $268 million, up 10% from a year earlier, led by DAYBUE sales of $101 million. Net income fell to $4 million, or $0.02 per diluted share, from $19 million, or $0.11, as selling, general and administrative expenses rose to $171 million from $126 million. The company reaffirmed its full year 2026 guidance, so shareholders see higher sales alongside lower profit.
Key points
- Total revenues were $268 million, up 10% from $244 million in Q1 2025; DAYBUE net sales rose 20% to $101 million and NUPLAZID GAAP net sales rose 5% to $167 million.
- Net income was $4 million, or $0.02 per diluted share, versus $19 million, or $0.11, in Q1 2025.
- SG&A expense rose to $171 million from $126 million, mainly from investments to support NUPLAZID and DAYBUE growth.
- 2026 guidance was reaffirmed, including total revenues of $1.22 to $1.28 billion; cash, cash equivalents and investment securities totaled $851 million at March 31, 2026.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:39 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 06, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.